Bank Julius Baer & Co
CCCC icon

Bank Julius Baer & Co’s C4 Therapeutics CCCC Stock Holding History

Bank Julius Baer & Co’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,905
Closed -$1.25M – 828
2021
Q1 		$1.25M Buy
+33,905
New +$1.35M 0.01% 313

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank Julius Baer & Co's CCCC Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of C4 Therapeutics (CCCC) in Q2 2021, closing a stake of 33,905 shares — an estimated $1.25M sold.

Bank Julius Baer & Co first reported a position in CCCC in Q1 2021 and held it in 1 quarter. The position peaked at $1.25M in Q1 2021. 107 funds tracked by Wall St. Rank hold CCCC as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining C4 Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 33,905 C4 Therapeutics shares in Q2 2021, an estimated $1.25M.
  • Bank Julius Baer & Co first reported a position in C4 Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's C4 Therapeutics position peaked at $1.25M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.